Literature DB >> 1419202

Discounting in health care decision-making: time for a change?

T A Sheldon1.   

Abstract

Economic appraisal is increasingly being used to inform health care decision-making. To allow comparison, costs and benefits spread over time are weighted according to when they are experienced. The further in the future, the less heavily they are weighted or the more they are discounted. Traditional economic appraisal techniques are based on the view that social decisions should reflect private preferences. The practice of discounting future streams of costs and benefits is principally justified by the fact that individuals have a positive time preference, preferring consumption sooner rather than later. Discounting weights public decision-making in favour of interventions resulting in short-term benefits and against longer-term benefits. This discriminates against preventive and other public health programmes. This paper provides a critique of the foundations of discounting. It is argued that health policy should have a longer time horizon, reflecting social values rather than individual preferences. Factors which make discounting the future rational from the individual's point of view are shown to be irrelevant to a societal perspective. Although uncertainty about the effectiveness of interventions and technological change are good reasons for weighting some future benefits less highly, the routine use of a single discount rate for economic evaluations of health programmes is not justified.

Mesh:

Year:  1992        PMID: 1419202

Source DB:  PubMed          Journal:  J Public Health Med        ISSN: 0957-4832


  13 in total

Review 1.  Economic notes. Discounting.

Authors:  D J Torgerson; J Raftery
Journal:  BMJ       Date:  1999-10-02

2.  Dimensions of time in managed care: metaphor or measure?

Authors:  M P Cotler
Journal:  HEC Forum       Date:  1997-12

Review 3.  Theoretical arguments for the discounting of health consequences: where do we go from here?

Authors:  Angelina Lazaro
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Why health economics is economical with the truth.

Authors:  J Munro
Journal:  Health Care Anal       Date:  1993-11

5.  Cost-effectiveness of new tests to diagnose and treat coronary heart disease.

Authors:  Leslee J Shaw; Allen J Taylor; Patrick G O'Malley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-08

6.  Modelling downstream effects in the presence of technological change.

Authors:  Duncan Mortimer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 7.  Discounting the future: influence of the economic model.

Authors:  R R West
Journal:  J Epidemiol Community Health       Date:  1996-06       Impact factor: 3.710

8.  Ante-natal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area.

Authors:  M J Dwyer; P G McIntyre
Journal:  Epidemiol Infect       Date:  1996-08       Impact factor: 2.451

9.  Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.

Authors:  P D Pharoah; W Hollingworth
Journal:  BMJ       Date:  1996-06-08

10.  Measuring the tail of the dog that doesn't bark in the night: the case of the national evaluation of Choose Life (the national strategy and action plan to prevent suicide in Scotland).

Authors:  Mhairi Mackenzie; Avril Blamey; Emma Halliday; Margaret Maxwell; Allyson McCollam; David McDaid; Joanne MacLean; Amy Woodhouse; Stephen Platt
Journal:  BMC Public Health       Date:  2007-07-06       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.